The Risk of Cardiovascular Disease and Diabetes in Rheumatoid Arthritis Patients: A Propensity Score Analysis
10.24304/kjcp.2019.29.2.109
- Author:
Kiyon RHEW
1
Author Information
1. College of Pharmacy, Dongduk Women's University, Seoul 02751, Republic of Korea. kiyon@dongduk.ac.kr
- Publication Type:Original Article
- Keywords:
Rheumatoid arthritis;
cardiovascular disease;
DMARD;
biologic agents
- MeSH:
Antirheumatic Agents;
Arthritis, Rheumatoid;
Biological Factors;
Cardiovascular Diseases;
Cerebral Infarction;
Comorbidity;
Diabetes Mellitus;
Drug Therapy;
Dyslipidemias;
Humans;
Hypertension;
Inflammation;
Insurance, Health;
Joints;
Logistic Models;
Myocardial Ischemia;
Odds Ratio;
Propensity Score;
Social Class;
Sports;
Synovial Membrane
- From:Korean Journal of Clinical Pharmacy
2019;29(2):109-114
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests as joint damage or athletic disability via sustained inflammation of the synovial membrane. The risk of cardiovascular disease (CVD) is higher in RA patients. This study aimed at evaluating the association between CVD comorbidities and RA by comparing a pharmacotherapy group with a non-pharmacotherapy group. METHODS: Patient sample data from the Health Insurance Review and Assessment Service (HIRA-NPS-2016) were used. Inverse probability of treatment weighting (IPTW) using the propensity score was used to minimize the differences in patient characteristics. Logistic regression analysis was used to evaluate the risk of CVD comorbidities. RESULTS: The analyses included 1,207,213 patients, of which 33,122 (2.8%) had RA. The odds ratios (OR) of CVD comorbidities were increased in RA patients; ischemic heart disease (IHD: OR 1.75; 95% CI 1.73, 1.77), cerebral infarction (CERI: OR 1.28; 95% CI 1.26, 1.30), hypertension (HTN: OR 1.44; 95% CI 1.43, 1.45), diabetes mellitus (DM: OR 2.04; 95% CI 2.03, 2.06), and dyslipidemia (DL: OR 3.49; 95% CI 3.47, 3.51). The ORs of IHD, CERI, HTN, and DM in the traditional DMARD and biologic treatment groups were decreased, compared with those in the non-pharmacotherapy group. CONCLUSIONS: Thus, CVD risk was higher in RA patients, considering age, sex, and socioeconomic status. Appropriate pharmacotherapy could decrease the risk of CVD comorbidities in RA patients.
